Cognitive and affective theory of mind in dementia with Lewy bodies and Alzheimer's disease.

Abstract:

BACKGROUND:Theory of mind (ToM) refers to the ability to attribute mental states, thoughts (cognitive component) or feelings (affective component) to others. This function has been studied in many neurodegenerative diseases; however, to our knowledge, no studies investigating ToM in dementia with Lewy bodies (DLB) have been published. The aim of our study was to assess ToM in patients with DLB and to search for neural correlates of potential deficits. METHODS:Thirty-three patients with DLB (DLB group) and 15 patients with Alzheimer's disease (AD group), all in the early stage of the disease, as well as 16 healthy elderly control subjects (HC group), were included in the study. After a global cognitive assessment, we used the Faux Pas Recognition (FPR) test, the Reading the Mind in the Eyes (RME) test and Ekman's Facial Emotion Recognition test to assess cognitive and affective components of ToM. Patients underwent cerebral 3-T magnetic resonance imaging, and atrophy of grey matter was analysed using voxel-based morphometry. We performed a one-sample t test to investigate the correlation between each ToM score and grey matter volume and a two-sample t test to compare patients with DLB impaired with those non-impaired for each test. RESULTS:The DLB group performed significantly worse than the HC group on the FPR test (P = 0.033) and the RME test (P = 0.015). There was no significant difference between the AD group and the HC group or between the DLB group and the AD group. Some brain regions were associated with ToM impairments. The prefrontal cortex, with the inferior frontal cortex and the orbitofrontal cortex, was the main region, but we also found correlations with the temporoparietal junction, the precuneus, the fusiform gyrus and the insula. CONCLUSIONS:This study is the first one to show early impairments of ToM in DLB. The two cognitive and affective components both appear to be affected in this disease. Among patients with ToM difficulties, we found atrophy in brain regions classically involved in ToM, which reinforces the neuronal network of ToM. Further studies are now needed to better understand the neural basis of such impairment.

journal_name

Alzheimers Res Ther

authors

Heitz C,Noblet V,Phillipps C,Cretin B,Vogt N,Philippi N,Kemp J,de Petigny X,Bilger M,Demuynck C,Martin-Hunyadi C,Armspach JP,Blanc F

doi

10.1186/s13195-016-0179-9

subject

Has Abstract

pub_date

2016-03-16 00:00:00

pages

10

issue

1

issn

1758-9193

pii

10.1186/s13195-016-0179-9

journal_volume

8

pub_type

杂志文章
  • Neuroimaging in repetitive brain trauma.

    abstract::Sports-related concussions are one of the major causes of mild traumatic brain injury. Although most patients recover completely within days to weeks, those who experience repetitive brain trauma (RBT) may be at risk for developing a condition known as chronic traumatic encephalopathy (CTE). While this condition is mo...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt239

    authors: Ng TS,Lin AP,Koerte IK,Pasternak O,Liao H,Merugumala S,Bouix S,Shenton ME

    更新日期:2014-02-24 00:00:00

  • Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.

    abstract:BACKGROUND:Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by neuropathologic changes involving beta-amyloid (Aβ), tau, neuronal loss, and other associated biological events. While levels of cerebrospinal fluid (CSF) Aβ and tau peptides have enhanced the antemortem detection of AD-specifi...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13195-018-0426-3

    authors: Gangishetti U,Christina Howell J,Perrin RJ,Louneva N,Watts KD,Kollhoff A,Grossman M,Wolk DA,Shaw LM,Morris JC,Trojanowski JQ,Fagan AM,Arnold SE,Hu WT

    更新日期:2018-09-25 00:00:00

  • Human amyloid-β enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization.

    abstract:BACKGROUND:Intracerebral inoculation of extracts from post-mortem human Alzheimer's disease brains into mice produces a prion-like spreading effect of amyloid-β. The differences observed between these extracts and the synthetic peptide, in terms of amyloid-β internalization and seed and cell-to-cell transmission of cyt...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0513-0

    authors: Pedrero-Prieto CM,Flores-Cuadrado A,Saiz-Sánchez D,Úbeda-Bañón I,Frontiñán-Rubio J,Alcaín FJ,Mateos-Hernández L,de la Fuente J,Durán-Prado M,Villar M,Martínez-Marcos A,Peinado JR

    更新日期:2019-06-29 00:00:00

  • A language-based sum score for the course and therapeutic intervention in primary progressive aphasia.

    abstract:BACKGROUND:With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential therapeutic effects. So far, volumetric brain changes have been proposed as clinical endpoints in the lit...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0345-3

    authors: Semler E,Anderl-Straub S,Uttner I,Diehl-Schmid J,Danek A,Einsiedler B,Fassbender K,Fliessbach K,Huppertz HJ,Jahn H,Kornhuber J,Landwehrmeyer B,Lauer M,Muche R,Prudlo J,Schneider A,Schroeter ML,Ludolph AC,Otto M,FTLD

    更新日期:2018-04-25 00:00:00

  • The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

    abstract:INTRODUCTION:Depression and psychosis are two of the most severe neuropsychiatric symptoms (NPS) in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Both NPS have negative effects on cognitive performance and life expectancy. The current study aimed to investigate and compare monoaminergic etiologies betwe...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-014-0090-1

    authors: Vermeiren Y,Van Dam D,Aerts T,Engelborghs S,Martin JJ,De Deyn PP

    更新日期:2015-02-11 00:00:00

  • Retinal microvasculature dysfunction is associated with Alzheimer's disease and mild cognitive impairment.

    abstract:BACKGROUND:The retina and brain share many neuronal and vasculature characteristics. We investigated the retinal microvasculature in Alzheimer's disease (AD) and mild cognitive impairment (MCI) using optical coherence tomography angiography (OCTA). METHODS:In this cross-sectional study, 24 AD participants, 37 MCI part...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00724-0

    authors: Chua J,Hu Q,Ke M,Tan B,Hong J,Yao X,Hilal S,Venketasubramanian N,Garhöfer G,Cheung CY,Wong TY,Chen CL,Schmetterer L

    更新日期:2020-12-04 00:00:00

  • Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody.

    abstract:BACKGROUND:Amyloid-β (Aβ) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer's disease (AD). Despite recent progress targeting aggregated forms of Aβ, low antibody brain penetrance remains a challenge. In the present study, we used transferrin receptor (TfR)-mediated transcytosis to f...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0377-8

    authors: Syvänen S,Hultqvist G,Gustavsson T,Gumucio A,Laudon H,Söderberg L,Ingelsson M,Lannfelt L,Sehlin D

    更新日期:2018-05-24 00:00:00

  • Alzheimer's disease drug-development pipeline: few candidates, frequent failures.

    abstract:INTRODUCTION:Alzheimer's disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. METHODS:We examined Clinical...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt269

    authors: Cummings JL,Morstorf T,Zhong K

    更新日期:2014-07-03 00:00:00

  • Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease.

    abstract:INTRODUCTION:There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testostero...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0107-4

    authors: Hall JR,Wiechmann AR,Cunningham RL,Johnson LA,Edwards M,Barber RC,Singh M,Winter S,O'Bryant SE,Texas Alzheimer’s Research and Care Consortium.

    更新日期:2015-05-01 00:00:00

  • Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease.

    abstract:INTRODUCTION:There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease (AD) assessed by repeated measures on serial tests of cognition and function. METHODS:Six hundre...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt7

    authors: Rountree SD,Chan W,Pavlik VN,Darby EJ,Siddiqui S,Doody RS

    更新日期:2009-10-21 00:00:00

  • Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.

    abstract:BACKGROUND:Kallikrein 6 (KLK6) is known to be an age-related protease expressed at high levels in the central nervous system. It was previously shown to be involved in proteolysis of extracellular proteins implicated in neurodegenerative diseases such as Alzheimer's disease (AD), prompting validation of KLK6 as a poten...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0336-4

    authors: Patra K,Soosaipillai A,Sando SB,Lauridsen C,Berge G,Møller I,Grøntvedt GR,Bråthen G,Begcevic I,Moussaud S,Minthon L,Hansson O,Diamandis EP,White LR,Nielsen HM

    更新日期:2018-01-29 00:00:00

  • Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.

    abstract:BACKGROUND:The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-making for multicentre research studies and clinical trials. In this study, we aimed at deriving reference Ce...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0478-z

    authors: Salvadó G,Molinuevo JL,Brugulat-Serrat A,Falcon C,Grau-Rivera O,Suárez-Calvet M,Pavia J,Niñerola-Baizán A,Perissinotti A,Lomeña F,Minguillon C,Fauria K,Zetterberg H,Blennow K,Gispert JD,Alzheimer’s Disease Neuroimaging Init

    更新日期:2019-03-21 00:00:00

  • LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1ΔE9 transgenic mice.

    abstract:BACKGROUND:Accumulating evidence implicates the neuroendocrine immunomodulation (NIM) network in the physiopathological mechanism of Alzheimer's disease (AD). Notably, we previously revealed that the NIM network is dysregulated in the PrP-hAβPPswe/PS1ΔE9 (APP/PS1) transgenic mouse model of AD. METHODS:After treatment ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-016-0226-6

    authors: Wang JH,Lei X,Cheng XR,Zhang XR,Liu G,Cheng JP,Xu YR,Zeng J,Zhou WX,Zhang YX

    更新日期:2016-12-13 00:00:00

  • Active immunotherapy options for Alzheimer's disease.

    abstract::Alzheimer's disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protein (Aβ) and/or hyperphosphorylated tau protein in the brain. At present, current therapies provide temporary sy...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt237

    authors: Winblad B,Graf A,Riviere ME,Andreasen N,Ryan JM

    更新日期:2014-01-30 00:00:00

  • Cognitive composite score association with Alzheimer's disease plaque and tangle pathology.

    abstract:BACKGROUND:Cognitive composite scores are used as the primary outcome measures for Alzheimer's disease (AD) prevention trials; however, the extent to which these composite measures correlate with AD pathology has not been fully investigated. Since many on-going AD prevention studies are testing therapies that target ei...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0401-z

    authors: Malek-Ahmadi M,Chen K,Perez SE,He A,Mufson EJ

    更新日期:2018-09-11 00:00:00

  • The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study.

    abstract:INTRODUCTION:Weight loss has been described in 20% to 45% of patients with Alzheimer's disease (AD) and has been associated with adverse outcomes. Various mechanisms for weight loss in AD patients have been proposed, though none has been proven. This study aimed to elucidate a mechanism of weight loss in AD patients by...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0098-1

    authors: Droogsma E,van Asselt D,Bieze H,Veeger N,De Deyn PP

    更新日期:2015-04-06 00:00:00

  • Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment.

    abstract:BACKGROUND:In patients with amyloid-positive mild cognitive impairment (MCI), neurodegenerative biomarkers such as medial temporal lobe atrophy (MTA) are useful to predict disease progression to dementia. Although posterior atrophy (PA) is a well-known neurodegenerative biomarker of Alzheimer's disease, little is known...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0326-y

    authors: Pyun JM,Park YH,Kim HR,Suh J,Kang MJ,Kim BJ,Youn YC,Jang JW,Kim S,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期:2017-12-16 00:00:00

  • Amyloid β-protein oligomers and Alzheimer's disease.

    abstract::The oligomer cascade hypothesis, which states that oligomers are the initiating pathologic agents in Alzheimer's disease, has all but supplanted the amyloid cascade hypothesis, which suggested that fibers were the key etiologic agents in Alzheimer's disease. We review here the results of in vivo, in vitro and in silic...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt226

    authors: Hayden EY,Teplow DB

    更新日期:2013-11-29 00:00:00

  • The effects of different familial Alzheimer's disease mutations on APP processing in vivo.

    abstract:BACKGROUND:Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer's disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a model for the sporadic form of AD. In FAD the diagnosis of AD is reliable and presymptomatic individu...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0234-1

    authors: Thordardottir S,Kinhult Ståhlbom A,Almkvist O,Thonberg H,Eriksdotter M,Zetterberg H,Blennow K,Graff C

    更新日期:2017-02-16 00:00:00

  • A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

    abstract:BACKGROUND:In Alzheimer's disease, beta-amyloid peptides in the brain aggregate into toxic oligomers and plaques, a process which is associated with neuronal degeneration, memory loss, and cognitive decline. One therapeutic strategy is to decrease the production of potentially toxic beta-amyloid species by the use of i...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章

    doi:10.1186/s13195-016-0178-x

    authors: Hölttä M,Dean RA,Siemers E,Mawuenyega KG,Sigurdson W,May PC,Holtzman DM,Portelius E,Zetterberg H,Bateman RJ,Blennow K,Gobom J

    更新日期:2016-03-07 00:00:00

  • Subcortical hyperintensity volumetrics in Alzheimer's disease and normal elderly in the Sunnybrook Dementia Study: correlations with atrophy, executive function, mental processing speed, and verbal memory.

    abstract:INTRODUCTION:Subcortical hyperintensities (SHs) are radiological entities commonly observed on magnetic resonance imaging (MRI) of patients with Alzheimer's disease (AD) and normal elderly controls. Although the presence of SH is believed to indicate some form of subcortical vasculopathy, pathological heterogeneity, me...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt279

    authors: Ramirez J,McNeely AA,Scott CJ,Stuss DT,Black SE

    更新日期:2014-08-11 00:00:00

  • Potential sources of interference on Abeta immunoassays in biological samples.

    abstract::Therapeutic products that depend on the use of an in vitro diagnostic biomarker test to confirm their effectiveness are increasingly being developed. Use of biomarkers is particularly meaningful in the context of selecting the patient population where the therapeutic treatment is believed to be efficacious (patient en...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt142

    authors: Vanderstichele H,Stoops E,Vanmechelen E,Jeromin A

    更新日期:2012-10-17 00:00:00

  • Utility of the Dependence Scale in dementia: validity, meaningfulness, and health economic considerations.

    abstract:BACKGROUND:The concept of dependence has been proposed as a unified representation of disease severity to quantify and stage disease progression in a manner more informative to patients, caregivers, and healthcare providers. METHODS:This paper provides a review of the Dependence Scale (DS) as a quantitative measure of...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-018-0414-7

    authors: Zhu CW,Bruinsma BG,Stern Y

    更新日期:2018-08-13 00:00:00

  • Dystrophic neurites express C9orf72 in Alzheimer's disease brains.

    abstract:INTRODUCTION:Chromosome 9 open reading frame 72 (C9orf72) is an evolutionarily conserved protein with unknown function, expressed at high levels in the brain. An expanded hexanucleotide GGGGCC repeat located in the first intron of the C9orf72 gene represents the most common genetic cause of familial frontotemporal deme...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt136

    authors: Satoh J,Tabunoki H,Ishida T,Saito Y,Arima K

    更新日期:2012-08-16 00:00:00

  • Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.

    abstract:BACKGROUND:Disclosure of amyloid positron emission tomography (PET) results to individuals without dementia has become standard practice in secondary prevention trials and also increasingly occurs in clinical practice. However, this is controversial given the current lack of understanding of the predictive value of a P...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0398-3

    authors: de Wilde A,van Buchem MM,Otten RHJ,Bouwman F,Stephens A,Barkhof F,Scheltens P,van der Flier WM

    更新日期:2018-07-28 00:00:00

  • Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph.

    abstract:BACKGROUND:Recent Genome Wide Association Studies (GWAS) have identified novel rare coding variants in immune genes associated with late onset Alzheimer's disease (LOAD). Amongst these, a polymorphism in phospholipase C-gamma 2 (PLCG2) P522R has been reported to be protective against LOAD. PLC enzymes are key elements ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0469-0

    authors: Magno L,Lessard CB,Martins M,Lang V,Cruz P,Asi Y,Katan M,Bilsland J,Lashley T,Chakrabarty P,Golde TE,Whiting PJ

    更新日期:2019-02-02 00:00:00

  • Systemic and central nervous system metabolic alterations in Alzheimer's disease.

    abstract:BACKGROUND:Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer's disease (AD) on both the systemic and central nervous system level. To study the extent and significance of these alterations in AD, quanti...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0551-7

    authors: van der Velpen V,Teav T,Gallart-Ayala H,Mehl F,Konz I,Clark C,Oikonomidi A,Peyratout G,Henry H,Delorenzi M,Ivanisevic J,Popp J

    更新日期:2019-11-28 00:00:00

  • Analysis of brain region-specific co-expression networks reveals clustering of established and novel genes associated with Alzheimer disease.

    abstract:BACKGROUND:Identifying and understanding the functional role of genetic risk factors for Alzheimer disease (AD) has been complicated by the variability of genetic influences across brain regions and confounding with age-related neurodegeneration. METHODS:A gene co-expression network was constructed using data obtained...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00674-7

    authors: Lancour D,Dupuis J,Mayeux R,Haines JL,Pericak-Vance MA,Schellenberg GC,Crovella M,Farrer LA,Kasif S

    更新日期:2020-09-02 00:00:00

  • Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimer's disease-associated markers in 3xTg-AD mice.

    abstract:BACKGROUND:Circulating autoantibodies and sex-dependent discrepancy in prevalence are unexplained phenomena of Alzheimer's disease (AD). Using the 3xTg-AD mouse model, we reported that adult males show early manifestations of systemic autoimmunity, increased emotional reactivity, enhanced expression of the histone vari...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00745-9

    authors: Kapadia M,Mian MF,Ma D,Hutton CP,Azam A,Narkaj K,Cao C,Brown B,Michalski B,Morgan D,Forsythe P,Zovkic IB,Fahnestock M,Sakic B

    更新日期:2021-01-20 00:00:00

  • Biomarkers in biological fluids for dementia with Lewy bodies.

    abstract::Dementia with Lewy bodies (DLB) has become the second most common neurodegenerative dementia due to demographic ageing. Differential diagnosis is still troublesome especially in early stages of the disease, since there is a great clinical and neuropathological overlap primarily with Alzheimer's disease and Parkinson's...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-014-0072-3

    authors: Schade S,Mollenhauer B

    更新日期:2014-10-16 00:00:00